menu search

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLC CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data supporting the […] The post Omega Therapeutics Presents New Preclinical Data Supporting the Pot... Read More
Posted: Oct 16 2023, 11:00
Author Name: forextv
Views: 091927

Search within

Pages Search Results: